Comment: Response Adaptive Randomization in Practice
Author:
Affiliation:
1. Scott M. Berry is President, Berry Consultants, 3345 Bee Caves Road Suite 201, Austin, Texas 78746, USA
2. Kert Viele is Director of Research, Berry Consultants, 3345 Bee Caves Road Suite 201, Austin, Texas 78746, USA
Publisher
Institute of Mathematical Statistics
Subject
Statistics, Probability and Uncertainty,General Mathematics,Statistics and Probability
Reference7 articles.
1. ALLAREDDY, V. and CHEIFETZ, I. M. (2019). Clinical trials and future directions in pediatric acute respiratory distress syndrome. Ann. Transl. Med. 7 514.
2. JONES, A. E., PUSKARICH, M. A., SHAPIRO, N. I. et al. (2018). Effect of levocarnitine vs placebo as an adjunctive treatment for septic shock: The rapid administration of carnitine in sepsis (RACE) randomized clinical trial. JAMA Netw. Open 1 e186076.
3. LEWIS, R. L., ANGUS, D. A., LATERRE, P. F., KJOLBYE, A. L., VAN DER MEULEN, E., BLEMINGS, A., GRAVES, T., RUSSELL, J. A., CARLSON, J. E. et al. (2018). Rationale and design of an adaptive phase 2b/3 clinical trial of selepressin for adults in septic shock. Selepressin evaluation programme for sepsis-induced shock-adaptive clinical trial. Ann. Amer. Thorac. Soc. 15 250–257.
4. SKRIVANEK, Z., BERRY, S., BERRY, D., CHIEN, J., GEIGER, M. J., ANDERSON, J. H. and GAYDOS, B. (2012). Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): Statistical design and simulations. J. Diabetes Sci. Technol. 6 1305–1318.
5. SWANSON, C. J., ZHANG, Y., DHADDA, S. et al. (2021). A randomized, double-blind, phase 2b proof-of- concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer’s Res. Ther. 13 80.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Effects of Allocation Method and Time Trends on Identification of the Best Arm in Multi-Arm Trials;Statistics in Biopharmaceutical Research;2024-01-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3